News

• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe

Research

• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
• Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
• Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
• Trajectories of prices in generic drug markets

General

• Generic drug growth in Brazil and Venezuela
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil

News

• FDA approves first natalizumab biosimilar Tyruko for MS
• EMA recommends approval of first natalizumab biosimilar Tyruko for MS
• EMA recommends approval of first aflibercept and tocilizumab biosimilars
• Alvotech: rejection AVT02 in the US and new partnerships with Prolifarma and Advanz Pharma

Research

• Ophthalmology biosimilars in Canada: a prescriber’s perspective
• Response to Opinion on: Four steps for streamlining biosimilars development
• Four steps for streamlining biosimilars development
• Biosimilars: US prescriber’s attitudes and perceptions revealed

General

• Coherus retracts AbbVie restraining order in Humira biosimilar dispute
• Proposal to widen access to trastuzumab in New Zealand
• GADECCU position statement on biosimilars updated
• GADECCU presents a new positioning on biosimilars

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links